Clinical TrialsThe company is expected to present updated results from the Phase 2 portion of the GRANITE study later this quarter, which could be a major catalyst for the stock.
Earnings And Financial PerformanceGritstone reported 2Q results slightly ahead of consensus estimates on lower-than-anticipated expenses.
Regulatory ProgressIf the positive early trends continue to strengthen, management is expected to meet with the FDA to finalize on the design of the Phase 3 portion as well as the regulatory path forward.